Patient Capital Management LLC Has $49.19 Million Stake in Crocs, Inc. $CROX

Patient Capital Management LLC lifted its position in shares of Crocs, Inc. (NASDAQ:CROX) by 17.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 588,794 shares of the textile maker’s stock after purchasing an additional 85,416 shares during the period. Crocs accounts for approximately 2.0% of Patient Capital Management LLC’s investment portfolio, making the stock its 26th biggest holding. Patient Capital Management LLC owned approximately 1.08% of Crocs worth $49,194,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Lisanti Capital Growth LLC acquired a new position in Crocs in the 2nd quarter valued at $3,138,000. Fort Washington Investment Advisors Inc. OH increased its position in shares of Crocs by 20.1% in the third quarter. Fort Washington Investment Advisors Inc. OH now owns 221,091 shares of the textile maker’s stock worth $18,472,000 after purchasing an additional 36,951 shares during the period. Voss Capital LP acquired a new position in Crocs in the second quarter valued at about $40,765,000. Lecap Asset Management Ltd. acquired a new position in Crocs in the second quarter valued at about $1,044,000. Finally, AlphaQuest LLC grew its stake in Crocs by 9,436.6% during the second quarter. AlphaQuest LLC now owns 7,820 shares of the textile maker’s stock worth $792,000 after buying an additional 7,738 shares in the last quarter. 93.44% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CROX has been the subject of a number of recent analyst reports. Baird R W downgraded shares of Crocs from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 7th. Weiss Ratings raised Crocs from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, January 12th. Robert W. Baird reissued a “neutral” rating and set a $100.00 price target on shares of Crocs in a report on Wednesday, January 7th. Wall Street Zen cut Crocs from a “buy” rating to a “hold” rating in a research report on Sunday, November 9th. Finally, Monness Crespi & Hardt increased their target price on shares of Crocs from $92.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Six research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $99.25.

Crocs Stock Performance

NASDAQ:CROX opened at $82.27 on Wednesday. The stock’s 50-day moving average is $85.29 and its 200-day moving average is $86.82. Crocs, Inc. has a 1-year low of $73.21 and a 1-year high of $122.84. The company has a current ratio of 1.40, a quick ratio of 0.83 and a debt-to-equity ratio of 0.97. The stock has a market cap of $4.27 billion, a P/E ratio of 26.80 and a beta of 1.54.

Crocs (NASDAQ:CROX) last posted its earnings results on Thursday, October 30th. The textile maker reported $2.92 EPS for the quarter, topping the consensus estimate of $2.36 by $0.56. Crocs had a net margin of 4.48% and a return on equity of 43.14%. The business had revenue of $996.30 million for the quarter, compared to the consensus estimate of $960.14 million. During the same period last year, the company earned $3.60 EPS. The firm’s revenue was down 6.2% compared to the same quarter last year. Crocs has set its Q4 2025 guidance at 1.820-1.92 EPS. Equities research analysts anticipate that Crocs, Inc. will post 13.2 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director John B. Replogle bought 3,000 shares of the stock in a transaction that occurred on Tuesday, November 11th. The stock was acquired at an average cost of $74.50 per share, with a total value of $223,500.00. Following the transaction, the director directly owned 18,417 shares in the company, valued at approximately $1,372,066.50. This trade represents a 19.46% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 2.72% of the stock is owned by insiders.

About Crocs

Crocs, Inc is a global footwear designer, developer and distributor best known for its lightweight, proprietary Croslite™ foam-clog construction. The company’s product portfolio encompasses a range of styles, including clogs, sandals, slides, boots and sneakers, all featuring the slip-resistant, odor-resistant and cushion-providing qualities of the Croslite material. Crocs distributes its products through an omnichannel network that includes e-commerce platforms, company-owned retail stores, authorized dealers and wholesale partners.

Founded in 2002 by Scott Seamans, Lyndon “Duke” Hanson and George Boedecker Jr., Crocs launched its first clog on the island of Vail, Colorado.